Non-Underwritten $2.2M Raise Puts Pressure on Percheron’s Clinical Progress

Capital Raise to Fuel Clinical Progress

Percheron Therapeutics Limited (ASX:PER), a biotechnology company focused on novel cancer therapies, has announced a non-renounceable entitlement offer to raise up to approximately $2.2 million. The offer is priced at $0.005 per share, representing a roughly 20% discount to the recent volume weighted average price, and includes free attaching options exercisable at $0.01 each over two years.

This capital raise is designed to provide the company with the necessary funds to advance its lead asset, HMBD-002, through a modular, multi-arm international phase II clinical trial targeting various cancers. The trial’s design allows Percheron to quickly identify promising treatment arms and focus resources accordingly, a strategy that could accelerate development timelines.

Offer Structure and Investor Incentives

Eligible shareholders are invited to subscribe for two new shares for every five shares held as of the record date, with one free option granted for every two new shares subscribed. These options provide an additional incentive, potentially allowing investors to benefit from future share price appreciation if the company’s clinical programs succeed.

Any shares and options not taken up in the entitlement offer will be made available under a shortfall offer, giving investors a chance to apply for additional securities subject to board discretion. Notably, the offer is not underwritten, which introduces some uncertainty about whether the full $2.2 million will be raised.

Strategic Use of Funds and Market Implications

Funds raised will primarily support the ongoing development of HMBD-002, which has already completed a phase I trial demonstrating safety and tolerability. The company aims to build on this foundation with the upcoming phase II study, expected to generate early efficacy data in multiple cancer indications. Additionally, proceeds will cover general working capital and costs associated with the offer itself.

Percheron’s approach reflects a cautious but optimistic step forward, balancing the need for capital with shareholder value preservation. The inclusion of free options may help mitigate dilution concerns, but investors will be watching closely to see how the market responds to the offer and subsequent clinical progress.

Next Steps and Timeline

The entitlement offer opened on March 24, 2026, and is scheduled to close on April 8, 2026, with new shares expected to commence trading on April 16. The company’s ability to secure full subscription and successfully execute its clinical plans will be key factors influencing its share price and investor confidence in the coming months.